ATRACURIUM BESYLATE INJECTION
SANDOZ CANADA INCORPORATED
This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.
Quick answers
Is ATRACURIUM BESYLATE INJECTION discontinued in Canada?
Yes. The manufacturer has reported to Health Canada that ATRACURIUM BESYLATE INJECTION has been permanently discontinued (last updated October 15, 2019). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.
Why is ATRACURIUM BESYLATE INJECTION not available?
The reason the manufacturer reported: Raw material availability.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Other Products
TRACRIUM
ABBVIE CORPORATION
NIMBEX 10MG/ML
ABBOTT LABORATORIES, LIMITED
NIMBEX
ABBVIE CORPORATION
ATRACURIUM - (FOR SINGLE DOSE )
IVAX PHARMACEUTICALS INCORPORATED
ATRACURIUM BESYLATE INJECTION
HOSPIRA HEALTHCARE ULC
ATRACURIUM - (FOR MULTIPLE DOSE VIAL - WITH PRESERVATIVE)
IVAX PHARMACEUTICALS INCORPORATED
What this means
Does this mean I need to switch medications right away?
Not necessarily right away, but this product will not be returning to the market.
What should I do?
Talk to your pharmacist or prescriber about your options well before your current supply runs out.
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
Low health risk
Possible match — not confirmed
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde is out of specification in the affected lots.
Low health risk
Possible match — not confirmed
DIN
02236759
Compare with another product →
Shortage History
Other Products from SANDOZ CANADA INCORPORATED
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
200MG · DIN 02243098
5MG · DIN 02269198
500MCG · DIN 02248181
250MG · DIN 02242971
50MG · DIN 02242325
DIN 02495929
DIN 02495910
DIN 02495937
250MG · DIN 02246533
1MG · DIN 02548968
10MG · DIN 02513420
5MG · DIN 02299925